Dianthus Therapeutics (DNTH) Competitors $37.90 +2.33 (+6.55%) Closing price 04:00 PM EasternExtended Trading$35.36 -2.54 (-6.70%) As of 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DNTH vs. AMRX, XENE, KYMR, CRNX, RARE, MOR, BHC, NAMS, HCM, and GMTXShould you be buying Dianthus Therapeutics stock or one of its competitors? The main competitors of Dianthus Therapeutics include Amneal Pharmaceuticals (AMRX), Xenon Pharmaceuticals (XENE), Kymera Therapeutics (KYMR), Crinetics Pharmaceuticals (CRNX), Ultragenyx Pharmaceutical (RARE), MorphoSys (MOR), Bausch Health Cos (BHC), NewAmsterdam Pharma (NAMS), HUTCHMED (HCM), and Gemini Therapeutics (GMTX). These companies are all part of the "pharmaceutical products" industry. Dianthus Therapeutics vs. Its Competitors Amneal Pharmaceuticals Xenon Pharmaceuticals Kymera Therapeutics Crinetics Pharmaceuticals Ultragenyx Pharmaceutical MorphoSys Bausch Health Cos NewAmsterdam Pharma HUTCHMED Gemini Therapeutics Dianthus Therapeutics (NASDAQ:DNTH) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends. Does the media favor DNTH or AMRX? In the previous week, Dianthus Therapeutics had 15 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 26 mentions for Dianthus Therapeutics and 11 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.09 beat Dianthus Therapeutics' score of 0.76 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 9 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 6 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend DNTH or AMRX? Dianthus Therapeutics presently has a consensus target price of $60.67, indicating a potential upside of 60.07%. Amneal Pharmaceuticals has a consensus target price of $11.60, indicating a potential upside of 18.13%. Given Dianthus Therapeutics' higher probable upside, analysts plainly believe Dianthus Therapeutics is more favorable than Amneal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dianthus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Amneal Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, DNTH or AMRX? Dianthus Therapeutics has higher earnings, but lower revenue than Amneal Pharmaceuticals. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDianthus Therapeutics$4.85M251.32-$84.97M-$3.25-11.66Amneal Pharmaceuticals$2.79B1.10-$116.89M$0.01982.00 Which has more risk & volatility, DNTH or AMRX? Dianthus Therapeutics has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Do institutionals and insiders believe in DNTH or AMRX? 47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 16.6% of Dianthus Therapeutics shares are owned by company insiders. Comparatively, 17.5% of Amneal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is DNTH or AMRX more profitable? Amneal Pharmaceuticals has a net margin of 0.12% compared to Dianthus Therapeutics' net margin of -2,364.56%. Dianthus Therapeutics' return on equity of -34.72% beat Amneal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Dianthus Therapeutics-2,364.56% -34.72% -32.72% Amneal Pharmaceuticals 0.12%-189.49%6.17% SummaryDianthus Therapeutics beats Amneal Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNTH vs. The Competition Export to ExcelMetricDianthus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.22B$3.15B$5.78B$10.04BDividend YieldN/A2.28%5.27%4.52%P/E Ratio-11.6621.4475.5026.08Price / Sales251.32428.01516.52171.73Price / CashN/A45.5837.2059.76Price / Book3.189.6011.536.20Net Income-$84.97M-$53.33M$3.29B$270.65M7 Day Performance56.22%0.61%0.44%2.70%1 Month Performance102.03%11.11%10.84%8.77%1 Year Performance36.33%12.61%61.62%27.39% Dianthus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNTHDianthus Therapeutics2.8799 of 5 stars$37.90+6.6%$60.67+60.1%+27.7%$1.22B$4.85M-11.6680Trending NewsAnalyst ForecastOptions VolumeGap DownHigh Trading VolumeAMRXAmneal Pharmaceuticals2.9936 of 5 stars$9.56+0.1%$11.60+21.3%+16.9%$3.00B$2.79B956.968,100Positive NewsXENEXenon Pharmaceuticals2.7687 of 5 stars$38.71+0.3%$53.20+37.4%-2.8%$2.98B$9.43M-10.90210Positive NewsKYMRKymera Therapeutics3.1445 of 5 stars$41.20-1.3%$58.76+42.6%-6.0%$2.95B$47.07M-11.87170Positive NewsCRNXCrinetics Pharmaceuticals3.6702 of 5 stars$30.99+1.1%$68.86+122.2%-30.1%$2.92B$1.04M-7.54210Positive NewsRAREUltragenyx Pharmaceutical4.3009 of 5 stars$29.96-1.1%$81.50+172.0%-43.5%$2.89B$560.23M-5.421,294Positive NewsAnalyst ForecastMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730BHCBausch Health Cos4.6034 of 5 stars$7.41+3.6%$9.00+21.5%+16.6%$2.75B$9.63B28.5020,700Positive NewsNAMSNewAmsterdam Pharma3.5795 of 5 stars$24.05+0.4%$41.55+72.7%+57.6%$2.71B$45.56M-14.854HCMHUTCHMED2.308 of 5 stars$15.01+1.2%$28.00+86.5%-7.2%$2.62B$630.20M0.001,811Analyst DowngradeGMTXGemini TherapeuticsN/A$59.650.0%N/A+23.0%$2.58BN/A-59.6530 Related Companies and Tools Related Companies Amneal Pharmaceuticals Alternatives Xenon Pharmaceuticals Alternatives Kymera Therapeutics Alternatives Crinetics Pharmaceuticals Alternatives Ultragenyx Pharmaceutical Alternatives MorphoSys Alternatives Bausch Health Cos Alternatives NewAmsterdam Pharma Alternatives HUTCHMED Alternatives Gemini Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DNTH) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DNTH Stock Alerts